文献速递腹部MR

钆贝葡胺给药后肝胆期肝脏强化与肝肾功能的相关性

Liver enhancement during hepatobiliary phase after Gd-BOPTA administration: correlation with liver and renal function.
PubMed 文献 · Eur Radiol · 2020-09-30

这项回顾性队列研究纳入两个中心2016年1月至2019年12月间326例接受钆贝葡胺增强1.5T肝脏MRI(注射后90-150分钟采集肝胆期)的患者,评估肝肾功能对肝胆期肝脏相对强化的影响。结果显示肝脏归一化相对强化与总胆红素呈负相关,与eGFR和采集延迟无显著相关;0.1 mmol/kg剂量组强化显著高于0.05 mmol/kg组,且0.1 mmol/kg可能对总胆红素>1.2 mg/dl的患者有用。

要点

  • 肝胆期肝脏归一化相对强化与总胆红素呈负相关,总胆红素>1.2 mg/dl者强化显著降低。
  • 肝脏归一化相对强化与eGFR及90-150分钟采集延迟无显著相关性。
  • 0.1 mmol/kg组肝脏归一化相对强化显著高于0.05 mmol/kg组(0.55 vs 0.33)。

核心结论

  • 肝胆期肝脏强化程度与eGFR或采集延迟无显著相关,但在肝功能受损患者中显著降低。
  • 0.1 mmol/kg钆贝葡胺剂量可能对总胆红素>1.2 mg/dl的患者有用。

研究设计与样本

  • IRB批准的回顾性队列研究,纳入两个中心2016年1月至2019年12月间326例接受钆贝葡胺增强1.5T肝脏MRI的患者。
  • 肝胆期于注射后90-150分钟采集;肝脏信号强度在平扫期和肝胆期测量,并以椎旁肌归一化。
  • 221/326例接受0.05 mmol/kg钆贝葡胺(A组),105/326例接受0.1 mmol/kg(B组)。
  • 采用Spearman r相关检验和Mann-Whitney U检验比较肝脏归一化相对强化与eGFR、总血清胆红素及肝胆期采集延迟的关系。

关键影像表现/征象

  • B组肝胆期肝脏归一化相对强化显著高于A组(0.55 vs 0.33,p<0.0001)。
  • 两组中肝胆期肝脏归一化相对强化均与总血清胆红素水平呈负相关(A组r=-0.32,p<0.0001;B组r=-0.36,p=0.0002)。
  • 总胆红素>1.2 mg/dl的患者肝胆期归一化相对强化显著低于总胆红素≤1.2 mg/dl者(A组p<0.0001;B组p=0.04)。
  • B组中肝功能受损患者的肝胆期归一化相对强化与A组中肝功能正常者相当。
  • 肝脏归一化相对强化与eGFR或采集延迟之间未观察到统计学显著相关性。

诊断标准与关键数值

  • 肝脏归一化相对强化:肝胆期肝脏信号强度经椎旁肌归一化后计算。
  • 总胆红素阈值为1.2 mg/dl,高于此值的患者肝胆期强化显著降低(A组p<0.0001;B组p=0.04)。
  • A组(0.05 mmol/kg)与B组(0.1 mmol/kg)的肝胆期肝脏归一化相对强化分别为0.33和0.55(p<0.0001)。

临床应用与阅片要点

  • 阅片时需注意总胆红素>1.2 mg/dl患者肝胆期肝脏强化可能降低,报告时应结合肝功能评估。
  • 肝胆期采集延迟在90-150分钟内对肝脏强化无显著影响,eGFR亦无显著影响。
  • 作者认为0.1 mmol/kg钆贝葡胺剂量可能对总胆红素>1.2 mg/dl的患者有用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the influence of liver and renal function on liver relative enhancement during hepatobiliary phase MRI after Gd-BOPTA administration.

METHODS: In this IRB-approved retrospective cohort study, we included 326 patients who underwent Gd-BOPTA-enhanced 1.5T liver MRI, including hepatobiliary phase (HBP) acquired 90-150 min after injection, in two centres between Jan 2016 and Dec 2019. Liver signal intensity was measured on native and HBP phases and normalized to paraspinal muscles. Liver normalized relative enhancement (NRE) in HBP was calculated and compared with eGFR, total serum bilirubin and HBP acquisition delay by means of Spearman r correlation test and Mann-Whitney U test.

RESULTS: 221/326 patients received 0.05 mmol/Kg Gd-BOPTA (group A), whereas 105/326 received 0.1 mmol/Kg (group B). Liver NRE in HBP was significantly higher in group B than in group A (0.55vs.0.33, p < 0.0001). In both groups, liver NRE in HBP had a negative correlation with total serum bilirubin level (r = - 0.32, p < 0.0001, group A; r = - 0.36, p = 0.0002, group B). Patients with total bilirubin > 1.2 mg/dl showed significantly lower NRE in HBP compared with those with total bilirubin ≤ 1.2 mg/dl (p < 0.0001, group A; p = 0.04, group B). Patients with impaired liver function in group B showed a NRE during HBP comparable with those with normal liver function in group A. No statistically significant correlation between liver NRE and eGFR or acquisition delay was observed.

CONCLUSIONS: The degree of liver enhancement during HBP is not correlated with eGFR or acquisition delay, but it is significantly reduced in patients with impaired liver function. 0.1 mmol/kg Gd-BOPTA dose might be useful in patients with total serum bilirubin > 1.2 mg/dl.

KEY POINTS: • The degree of liver enhancement during hepatobiliary phase after Gd-BOPTA administration has a negative correlation with total serum bilirubin level (r = - 0.32, p < 0.0001). • The degree of liver enhancement during HBP after Gd-BOPTA administration is not significantly correlated with renal function and acquisition delay (comprised between 90 and 150 min after contrast injection). • 0.1 mmol/Kg Gd-BOPTA dose might be preferable in patients with increased total serum bilirubin levels.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Bonatti M, Valletta R, Avesani G, et al. Liver enhancement during hepatobiliary phase after Gd-BOPTA administration: correlation with liver and renal function. Eur Radiol. 2020. PMID: 33000303. doi:10.1007/s00330-020-07279-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。